TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01886157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection + Trigger Splint+ Education and Home exercises
Description: Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Standard trigger finger corticosteroid injection.
Study: NCT00652613

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3 Dimensional Radiation Therapy
Description: Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
Study: NCT04432584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered at a dose of 1000 mg IV (for participants with body weight between 40 and 100kg) or 1500 mg IV (for participants with body weight \>=100kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100kg) or 1020 mg SC (for participants with body weight \>=100kg). Dosing schedule will be as described above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eculizumab
Description: Eculizumab will be administered at a dose of 900 mg every 2 weeks, as per the dosing schedule described above.
Study: NCT01665027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum
Description: Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).~Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: routine manual maneuvers for fetal head extraction
Description: fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
Study: NCT01051167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
Study: NCT03247244

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 10%, CBD \<0.5%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 10%, CBD \<0.5%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 10%, CBD \<0.5%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 10%, CBD \<0.5%
Study: NCT02000154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB L-1101
Description: SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
Study: NCT02374047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054
Study: NCT01075425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belinostat
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies
Study: NCT02894515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine commercial tablet (test)
Description: single dose, 10 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine commercial tablet (test)
Description: single dose, 10 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine clinical tablet (reference)
Description: single dose, 10 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine clinical tablet (reference)
Description: single dose, 10 mg, oral
Study: NCT00097266

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, oral, 15-30 mg, once daily, 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Capsule, oral, 5-15 mg, once daily, 12 weeks.
Study: NCT01513915

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group cognitive behavioral intervention
Description: A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
Study: NCT01612910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral microencapsulated diindolylmethane
Description: Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00758615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking School Bus
Description: Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
Study: NCT02556762

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy with simultaneous modulated accelerated boost
Description: Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose radiotherapy
Description: Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF
Description: Chemotherapy: Cisplatin and 5fluorouracil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PF
Description: Chemotherapy: Cisplatin and 5fluorouracil
Study: NCT01304823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed liquid meal
Description: Ensure Plus

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mixed liquid meal
Description: Ensure Plus
Study: NCT04160013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discipline education
Description: Discipline education using the Play Nicely program.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cavity Prevention
Description: Cavity prevention using a 2 page handout.
Study: NCT03247244

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 8.6%, CBD 8.6%
Study: NCT01811030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755nm Alexandrite Laser
Description: 755nm Alexandrite Laser
Study: NCT03247244

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 8.6%, CBD 8.6%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 8.6%, CBD 8.6%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 8.6%, CBD 8.6%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 0.6%, CBD 14%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 0.6%, CBD 14%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 0.6%, CBD 14%

Intervention type: DRUG
Group type: OTHER
Intervention: Cannabis
Description: THC 0.6%, CBD 14%
Study: NCT01503801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: respiratory support
Description: Routine respiratory support.
Study: NCT03589313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3067 single dose
Description: GLPG3067 film coated tablets provided at Day 1.
Study: NCT03246763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated community-healthcare childhood obesity treatment
Description: The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated community-healthcare childhood obesity treatment
Description: The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments.
Study: NCT02374047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAT-2054-C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT04785521

Intervention type: RADIATION
Intervention: Stereotactic radiosurgery
Description: Gamma Knife stereotactic radiosurgery (SRS-GK)

Intervention type: RADIATION
Intervention: Stereotactic radiosurgery
Description: Gamma Knife stereotactic radiosurgery (SRS-GK)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
Study: NCT03246763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated community-healthcare childhood obesity treatment
Description: The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments.
Study: NCT03070145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: 12-week moderate-intensity aerobic and strength training exercise intervention
Study: NCT04208932

Intervention type: DRUG
Intervention: SSRIs
Description: Selective Serotonin Reuptake Inhibitors
Study: NCT03380741

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour markers detection
Description: Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
Study: NCT03913676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Velibra
Description: Velibra is grounded in a cognitive-behavioral theoretical orientation and consists of six treatment modules representing different skills and therapeutic techniques. Each of the first five modules is followed by a training session, and contains activities related to training attention biases (CBM-I). All sessions plus trainings are designed to be completed in 1 - 2 hours, depending on the user's reading speed, interest, motivation, and individual path through the program. The modules cover a variety of therapeutic content that is broadly consistent with a cognitive-behavioral perspective. The modules' content draws from therapeutic strategies: (1) Cognitive Modification, (2) Mindfulness, Acceptance, and Relaxation techniques (4) Exposure, (5) Interpersonal Skills, (6) Psychoeducation and Relapse Prevention.
Study: NCT04532684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study: NCT03553979

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management program (SM)
Description: Participants follow the SM program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress management + Buddy program (SM-B)
Description: In addition to receiving the SM, participants in the SM-B will also receive one-to-one support through a buddy.
Study: NCT03873272

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotherapy
Description: Study subjects will wear NatraCure flexible socks on bilateral hands and feet. The sock will act as a mitten and covers the entire hand until past the wrist. There are 2 gel packs inserted into the sock, to provide cooling to the dorsal and frontal aspect of the hand. For the feet, the sock will cover the entire foot until above the ankle. Garments will be refrigerated for at least 3 hours at -25 to -30 Celsius prior to use. With each infusion, patients will wear the frozen garments on their hands and feet for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion. Two sets of socks will be used during each session for 45-60 minutes each to maintain a consistently low temperatures of the extremities.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Compression Therapy
Description: Study participants will wear Sigvaris Secure Arm Sleeves and Gloves on bilateral upper extremities. The sleeves and gloves provide 20-30mmHg of compression. Subjects will wear Sigvaris CompreFlex Lite compression garments on the lower extremities which includes a transition liner with a compressive foot, providing 20-30mmHg of compression on the lower leg and 15mmHg on the toes and feet. AccuTabs will be placed along the CompreFlex Lite to easily and accurately set the compression level at 20-30mmHg. With each chemotherapy infusion, patients will wear the sleeves/gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Loose glove/sock
Description: Study participants will wear a non-compressive sleeve and loosely fitting glove on bilateral arms and hands. They will also wear a non-compressive Sigvaris Basic Liner with the CompreFlex Lite loosely applied over it. The investigators will verify that no compression is applied via using an interface pressure sensor (PicoPress). The maximum level of allowed pressure for garments will be 3mmHg. If the pressure reading is greater than 3mmHg, then a larger garment size will be used. Measurements with the pressure sensor will be repeated as needed to ensure a low pressure level of less than 3mmHg. With each chemotherapy infusion, patients will wear the gloves and socks for a total of 90-120 minutes, beginning 15 minutes before the start of the infusion and until 15 minutes after the end of the infusion.
Study: NCT03380741

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour markers detection
Description: Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour markers detection
Description: Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumour markers detection
Description: Lab on a chip detection of tumour markers measured from vaginal/cervical cytology swab
Study: NCT02015715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6864018
Description: A single oral ascending dose of RO6864018 capsules on Day 1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single oral dose of placebo matching RO6864018 capsules on Day 1.
Study: NCT02370394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ROSE Program
Description: The ROSE Program was specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It was tailored to the current IPV risk assessment, pregnancy or postpartum status of each participant, was designed to reach participants across levels of motivation for change. The content of ROSE was theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
Study: NCT04452838

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Description: 4 mg administered under fasted condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Description: 4 mg administered under fasted condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Description: 4 mg administered under fasted condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Description: 4 mg administered under fasted condition.

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B)
Description: 4 mg administered under fasted condition.
Study: NCT03115255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravitreal ranibizumab
Description: 0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
Study: NCT04785521

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood samples
Description: Serum Glu levels and Glu-regulation markers assessed prior to and following SRS-GK in BM or benign lesions or at baseline in non-BM patients.
Study: NCT02453841

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxymetazoline